Psychedelic Spotlight News

  • New Players, BUY Ratings, Financial Results & MORE ( MINDMED, NUMI, CMPS, MYCO, FTRP, HAVN, DMT)

    Listen, Videos

    There were A LOT OF DEVELOPMENTS THIS WEEK, so strap on your seat belts and let’s dive into what happened this week with: MindMed ( MMED / MNMD / MMQ ), Compass Pathways (CMPS), NUMINUS (NUMI), Fieldtrip Health (FTRP / FTRPF), Mydecine ( MYCO / MYCOF), HAVN Labs
    ( HAVN / HAVLF), Novamind ( NM / NVMDF), Champignon Brands aka Braxia Scientific
    (old ticker :SHRM / new ticker: BRAX / BRAXF), Nova Mentis (NOVA / NMLSF) and Small Pharma (DMT).

    Timestamps:
    0:00 – Intro
    0:54 – MindMed’s (MMED / MNMD) Project Angie Announcement
    1:47 – Compass Pathways (CMPS) Q1 Financial Results Date & Business Updates
    3:16 – Analyst Coverage and Buy Ratings for CMPS
    4:35 – Mydecine ( MYCO / MYCOF) 2020 Financial Results & Business Highlights
    9:17 – Numinus Wellness (NUMI) Q2 Financial Results
    11:25 – Field Trip Health (FTRP/ FTRPF) Opens more clinics
    12:19 – Novamind ( NM / NVMDF) doubling its clinics
    14:25 – Champignon Brands (SHRM /SHRMF) changing its named to Braxia Scientific (BRAX / BRAXF)
    15:31 – NEW DMT company that began trading on may 6th under the name SMALL PHARMA ( DMT)
    17:19 – HAVN Labs (HAVN) opens a new lab in Jamaica
    17:50 – Nova Mentis launches a new clinical study using psilocybin to treat autism

    Link to MindMed’s Project Angie Press release:
    https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

    Link to Compass Pathways Q1 financial Results date:
    https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announce-first-quarter-2021-financial

    Link to Compass Pathways (CMPS) analyst ratings: https://www.marketbeat.com/stocks/NASDAQ/CMPS/price-target/

    Link to Mydecine ( MYCO/ MYCOF) Full Year 2020 Financial results Plus business updates
    https://www.globenewswire.com/news-release/2021/05/03/2221266/0/en/Mydecine-Reports-Full-Year-2020-Financial-Results-and-Provides-Business-Update.html

    Link to Numinus (NUMI) Q2 2021 Financial Results:
    https://www.newswire.ca/news-releases/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing-mindspace-wellbeing-acquisition-and-clinical-trial-collaboration-with-maps-pbc-846735411.html

    Link to Field Trip’s (FTPR / FTPRF) 7th Psychedelic-assisted therapy Clinic:
    https://psilocybinalpha.com/news/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston-locations-of-next-5-field-trip-health-centers

    Link to Novamind’s (NM / NVMDF) Ketamine Clinic article:
    https://novamind.ca/2021-05-04-novamind-doubles-in-size-adds-four-new-psychedelic-mental-health-clinics/

    Link to Champignon Brands ( SHRM/ SHRMF) announcing their name change to Braxia Scientific (BRAX / BRAXF):
    https://thedeepdive.ca/champignon-brands-to-change-name-to-braxia-scientific/

    Link to Small Pharma ( DMT):
    https://psilocybinalpha.com/news/small-pharma-completes-reverse-take-over-transaction

    Link to Havn’s (HAVN / HAVLF) Jamaica lab:
    https://www.psychedelicfinance.com/articles/havn-labs-jamaica-facility-now-fully-operational

    Link to Nova Mentis launching a clinical study to learn more about Autism:
    https://psilocybinalpha.com/news/nova-mentis-launches-autism-clinical-study

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    editing by: @themyaholy
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #Numi #CMPS

  • AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

    Learn, Videos

    AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results) Today, we’ll be sharing some GAME changing news for the entire psychedelic-medicines industry!

    First, we’ll start with some inspiring results from a few MDMA studies and their implications for companies such as Numinus (NUMI), MindMed (MMED / MNMD / MMQ) and Atai Life Sciences. First we’ll cover MAPS’ Phase III MDMA To Treat PTSD Trial Results. Then, we’ll focus on another study’s results, which implies that MDMA could be an effective treatment for alcoholism.

    Then, we’ll shift our focus towards an update on Texas, one of the more conservative U.S. states, and its approval of a Psychedelics Research Bill.

    Finally, we’ll share some of the oddest and most exciting news from this week: AI might potentially disrupt the psychedelic industry in the next few decades through the creation of psychedelic medicines.

    Timestamps:

    0:00 – Intro
    1:24 – Maps Phase III Trial Testing MDMA to treat PTSD RESULTS & Implications for
    Numinus (NUMI), MindMed (MMED / MNMD / MMQ ), Atai, etc.
    3:23 – Imperial College of London Study testing MDMA-assisted psychotherapy to treat Alcoholism
    7:29 – Texas House Approves a Psychedelic Research Bill
    9:34 – Scientists are Using AI to Develop New Psychedelic Drugs

    Links to Maps Phase III MDMA trial to treat PTSD : https://www.nytimes.com/2021/05/03/health/mdma-approval.html
    https://maps.org/news/media/9122-maps-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-achieves-successful-results-for-patients-with-severe-chronic-ptsd

    Links to the Imperial College of London MDMA study to treat alcoholism: https://www.telegraph.co.uk/health-fitness/body/mdma-cured-alcoholism-inside-remarkable-ectsasy-trial-offering/
    https://www.telegraph.co.uk/news/2021/02/22/mdma-could-used-treat-alcohol-addiction/

    Link to the Texas House Psychedelics Research Bill: https://www.marijuanamoment.net/texas-house-approves-psychedelics-research-bill-as-marijuana-reform-measures-also-advance/

    Link to the article “Scientists are Using AI to Develop New Psychedelic Drugs: https://doubleblindmag.com/artificial-intelligence/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #MNMD

  • MindMed Taking On The $30 BILLION Pain Relief Industry? [MMED / MNMD Expanding with Project Angie ]

    Listen, Videos

    Project Angie: Can MindMed Disrupt the Pain Relief Industry? [MMED / MNMD Expanding Horizons]
    Breaking NEWS: MindMed ( MNMD / MMED / MMQ ) launching a new flagship program called Angie to advance the development of psychedelics, including LSD and potentially penetrate the pain killer industry by treating pain conditions. MindMed is currently exploring two primary clinical indications for the treatment of pain:

    MindMed will initiate a study of LSD in a severe pain indication. MMED is currently preparing a pre-IND briefing package for this Phase 2a Proof of Concept study. They plan to submit to the FDA in the second half of 2021.
    ( As a note, that means they could present this doc anywhere between July 1st and December 31st. So it is conceivable that this trial could start at the tail end of 2021, if this doc gets presented at the beginning of that period.)
    The second indication that MindMed is evaluating is “the common, often debilitating, chronic pain syndrome”.

    Link to the 1964 study testing the LSDs ability to treat pain in cancer patients, and it had dual surprising results

    : file:///C:/Users/maria/Downloads/Study_of_Lysergic_Acid_Diethylamide_as_an.13.pdf
    Link to the 2020 a study was published that had among its authors 2 prominent MindMed collaborators: Mattias Liechti and Kim Kuypers: https://journals.sagepub.com/doi/full…​
    Link to the 2017study: https://www.ncbi.nlm.nih.gov/pmc/arti…​

    Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/​
    Link to MindMed ‘ s Press Release on Project Angie : https://mindmed.co/news/press-release…​

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa…​
    https://benzinga.grsm.io/thepsychedel…​

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed​ #MindMedStock​ #MNMD